The safety and efficacy of AMVUTTRA were evaluated in an 18-month study of 164 adult patients with polyneuropathy caused by hATTR amyloidosis.
The clinical study of AMVUTTRA focused on changes in nerve function and quality of life.
The effects of AMVUTTRA on other aspects of the disease, including walking speed, nutritional health, and ability to perform activities of daily living, were also evaluated.
The efficacy of AMVUTTRA was evaluated using multiple assessments.
These assessments were performed at 9 months and again at 18 months.
Efficacy was determined by comparing results
- Patients treated with AMVUTTRA
- Patients from a similar study who were given a placeboa
aPlacebo: treatment without any active medication.